Exchange / Market
Formed in April 2012 when the Abbott Laboratories group™ pharmaceutical and biological product divisions split off, AbbVie specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohns disease, thyroid disease, Parkinsons disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Sales are distributed geographically as follows: United States (55.7%), Netherlands (5.2%), Germany (4%), Japan (3.5%), Spain (3.3%), France (3%), United Kingdom (2.8%), Canada (2.6%), Italy (2.4%), Brazil (2.2%), and other (15.3%).
Initial Public offering
Listing date: 20/12/2012